Literature DB >> 26740106

Human Head and Neck Squamous Cell Carcinoma-Associated Semaphorin 4D Induces Expansion of Myeloid-Derived Suppressor Cells.

Rania H Younis1, Kyu Lee Han2, Tonya J Webb3.   

Abstract

One of the mechanisms by which malignancies can induce immune suppression is through the production of cytokines that affect the maturation and differentiation of inflammatory cells in the tumor microenvironment. Semaphorin 4D (Sema4D) is a proangiogenic cytokine produced by several malignancies, which has been described in the regulation of the immune system. In the present study, we examined the role of human head and neck squamous cell carcinoma (HNSCC)-secreted Sema4D on myeloid cell differentiation. CD33(+) cells cultured in HNSCC cell line-derived conditioned medium differentiated into myeloid derived suppressor cells (MDSC) (CD33(+)CD11b(+)HLA-DR(-/low)). The addition of anti-Sema4D Ab to HNSCC conditioned medium significantly reduced the expansion of the MDSC population. Similarly, knockdown of Sema4D in an HNSCC cell line resulted in a loss of MDSC function as shown by a decrease in the production of the immune-suppressive cytokines arginase-1, TGF-β, and IL-10 by MDSC, concomitant with recovery of T cell proliferation and IFN-γ production following stimulation of CD3/CD28. Importantly, CD33(+) myeloid and T cells cultured in conditioned medium of HNSCC cells in which Sema4D was knocked down promoted antitumor inflammatory profile, through recovery of the effector T cells (CD4(+)T-bet(+) and CD8(+)T-bet(+)), as well as a decrease in regulatory T cells (CD4(+)CD25(+)FOXP3(+)). We also showed that Sema4D was comparable to GM-CSF in its induction of MDSC. Collectively, this study describes a novel immunosuppressive role for Sema4D in HNSCC through induction of MDSC, and it highlights Sema4D as a therapeutic target for future studies to enhance the antitumorigenic inflammatory response in HNSCC and other epithelial malignancies.
Copyright © 2016 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26740106      PMCID: PMC4722498          DOI: 10.4049/jimmunol.1501293

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  67 in total

1.  Semaphorin 4D expression is associated with a poor clinical outcome in cervical cancer patients.

Authors:  Huidong Liu; Yanmei Yang; Jianbing Xiao; Shucai Yang; Yan Liu; Wenhui Kang; Xinlei Li; Fengmin Zhang
Journal:  Microvasc Res       Date:  2014-03-03       Impact factor: 3.514

2.  [Antiangiogenic and anti-immunosuppressive therapeutic strategies in human head and neck squamous cell carcinoma (HNSCC)].

Authors:  L Strauss; D Volland; A Guerrero; T Reichert
Journal:  Mund Kiefer Gesichtschir       Date:  2005-09

3.  Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13.

Authors:  Rachel F Gabitass; Nicola E Annels; Deborah D Stocken; Hardev A Pandha; Gary W Middleton
Journal:  Cancer Immunol Immunother       Date:  2011-06-05       Impact factor: 6.968

4.  USC-HN2, a new model cell line for recurrent oral cavity squamous cell carcinoma with immunosuppressive characteristics.

Authors:  Sarah M Russell; Melissa G Lechner; Lucy Gong; Carolina Megiel; Daniel J Liebertz; Rizwan Masood; Adrian J Correa; Jing Han; Raj K Puri; Uttam K Sinha; Alan L Epstein
Journal:  Oral Oncol       Date:  2011-06-29       Impact factor: 5.337

Review 5.  Myeloid progenitor cells mediate immune suppression in patients with head and neck cancers.

Authors:  M R Young; D M Lathers
Journal:  Int J Immunopharmacol       Date:  1999-04

Review 6.  Immunobiologic aspects of head and neck cancer. Clinical and laboratory correlates.

Authors:  D R Vlock
Journal:  Hematol Oncol Clin North Am       Date:  1991-08       Impact factor: 3.722

7.  Induction of myeloid-derived suppressor cells by tumor exosomes.

Authors:  Xiaoyu Xiang; Anton Poliakov; Cunren Liu; Yuelong Liu; Zhong-bin Deng; Jianhua Wang; Ziqiang Cheng; Spandan V Shah; Gui-Jun Wang; Liming Zhang; William E Grizzle; Jim Mobley; Huang-Ge Zhang
Journal:  Int J Cancer       Date:  2009-06-01       Impact factor: 7.396

8.  Cytokines IL-1 alpha, IL-6, and GM-CSF constitutively secreted by oral squamous carcinoma induce down-regulation of CD80 costimulatory molecule expression: restoration by interferon gamma.

Authors:  Giovana R Thomas; Zhong Chen; Elena Leukinova; Carter Van Waes; Judy Wen
Journal:  Cancer Immunol Immunother       Date:  2003-10-09       Impact factor: 6.968

9.  Mechanisms of immune suppression in patients with head and neck cancer: presence of CD34(+) cells which suppress immune functions within cancers that secrete granulocyte-macrophage colony-stimulating factor.

Authors:  A S Pak; M A Wright; J P Matthews; S L Collins; G J Petruzzelli; M R Young
Journal:  Clin Cancer Res       Date:  1995-01       Impact factor: 12.531

10.  Functional characterization of human Cd33+ and Cd11b+ myeloid-derived suppressor cell subsets induced from peripheral blood mononuclear cells co-cultured with a diverse set of human tumor cell lines.

Authors:  Melissa G Lechner; Carolina Megiel; Sarah M Russell; Brigid Bingham; Nicholas Arger; Tammy Woo; Alan L Epstein
Journal:  J Transl Med       Date:  2011-06-09       Impact factor: 5.531

View more
  26 in total

1.  Semaphorin4D Inhibition Improves Response to Immune-Checkpoint Blockade via Attenuation of MDSC Recruitment and Function.

Authors:  Paul E Clavijo; Jay Friedman; Yvette Robbins; Ellen C Moore; Ernest Smith; Maurice Zauderer; Elizabeth E Evans; Clint T Allen
Journal:  Cancer Immunol Res       Date:  2018-12-04       Impact factor: 11.151

Review 2.  Myeloid-Derived Suppressor Cells: Immune-Suppressive Cells That Impair Antitumor Immunity and Are Sculpted by Their Environment.

Authors:  Suzanne Ostrand-Rosenberg; Catherine Fenselau
Journal:  J Immunol       Date:  2018-01-15       Impact factor: 5.422

3.  Anti-PD-L1 Efficacy Can Be Enhanced by Inhibition of Myeloid-Derived Suppressor Cells with a Selective Inhibitor of PI3Kδ/γ.

Authors:  Ruth J Davis; Ellen C Moore; Paul E Clavijo; Jay Friedman; Harrison Cash; Zhong Chen; Chris Silvin; Carter Van Waes; Clint Allen
Journal:  Cancer Res       Date:  2017-03-31       Impact factor: 12.701

Review 4.  Semaphorins 4A and 4D in chronic inflammatory diseases.

Authors:  Svetlana P Chapoval; Zahava Vadasz; Andrei I Chapoval; Elias Toubi
Journal:  Inflamm Res       Date:  2016-08-23       Impact factor: 4.575

Review 5.  The 'Danse Macabre'-Neutrophils the Interactive Partner Affecting Oral Cancer Outcomes.

Authors:  Sara Hadjigol; Bansari A Shah; Neil M O'Brien-Simpson
Journal:  Front Immunol       Date:  2022-06-16       Impact factor: 8.786

6.  Principal component analysis of early immune cell dynamics during pembrolizumab treatment of advanced urothelial carcinoma.

Authors:  Taro Teshima; Yukari Kobayashi; Taketo Kawai; Yoshihiro Kushihara; Koji Nagaoka; Jimpei Miyakawa; Yoshiyuki Akiyama; Yuta Yamada; Yusuke Sato; Daisuke Yamada; Nobuyuki Tanaka; Tatsuhiko Tsunoda; Haruki Kume; Kazuhiro Kakimi
Journal:  Oncol Lett       Date:  2022-06-16       Impact factor: 3.111

Review 7.  Transmembrane semaphorins: Multimodal signaling cues in development and cancer.

Authors:  Sreeharsha Gurrapu; Luca Tamagnone
Journal:  Cell Adh Migr       Date:  2016-06-13       Impact factor: 3.405

8.  Resistance to CTLA-4 checkpoint inhibition reversed through selective elimination of granulocytic myeloid cells.

Authors:  Paul E Clavijo; Ellen C Moore; Jianhong Chen; Ruth J Davis; Jay Friedman; Young Kim; Carter Van Waes; Zhong Chen; Clint T Allen
Journal:  Oncotarget       Date:  2017-06-11

Review 9.  Tumor immune microenvironment in head and neck cancers.

Authors:  Samantha M Y Chen; Alexandra L Krinsky; Rachel A Woolaver; Xiaoguang Wang; Zhangguo Chen; Jing H Wang
Journal:  Mol Carcinog       Date:  2020-02-03       Impact factor: 4.784

10.  Semaphorin 4D in human head and neck cancer tissue and peripheral blood: A dense fibrotic peri-tumoral stromal phenotype.

Authors:  Roshanak Derakhshandeh; Sonia Sanadhya; Kyu Lee Han; Haiyan Chen; Olga Goloubeva; Tonya J Webb; Rania H Younis
Journal:  Oncotarget       Date:  2018-01-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.